ChemoCentryx Inc Logo Image

ChemoCentryx Inc

ChemoCentryx Inc Banner Image

Most Recent Annual Report

2019 Annual Report and Form 10K

ChemoCentryx Inc

ChemoCentryx Inc does not currently have any hardcopy reports on Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About ChemoCentryx Inc

51-200 Employees
Based in Mountain View, California

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates in clinical development include CCX140 that has completed a Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; CCX872, an orally administered inhibitor that is under Phase Ib clinical trial for pancreatic cancer; and CCX168, which has completed a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic anti-body associated renal vasculitis.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol